Neovacs S.A SMA 50
What is the SMA 50 of Neovacs S.A?
The SMA 50 of Neovacs S.A. is €0 +100.00%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with sma 50 similar to Neovacs S.A
- Neovacs S.A has SMA 50 of €0 +100.00%
- EVmo Inc has SMA 50 of $0 +99.75%
- Blue Capital Reinsurance Ltd has SMA 50 of $0 -Inf%
- Kaleido Biosciences Inc has SMA 50 of $0 +59.40%
- Yangtze River Port and Logistics Ltd has SMA 50 of $0 +28.25%
- iFresh Inc has SMA 50 of $0 +0.00%
- Aridis Pharmaceuticals Inc has SMA 50 of $0 +83.25%